Zdrowie i gospodarka · 11/02/2013
FDA Releases Draft Guidance on Assessing Immunogenicity in Therapeutic Protein Products
The FDA has made available a draft guidance to help pharmaceutical manufacturers assess and mitigate potential immune responses in therapeutic protein products, which can lead to serious adverse events or loss of efficacy.
Source: Federal Register — Food and Drug AdministrationOpen original release →